BioNTech SE · NASDAQ:BNTX
BioNTech — Shareholder Meeting (May 2025)
31 slides from BioNTech's shareholder meeting presentation, May 16, 2025
Slide 1: Annual General Meeting
Annual General Meeting 16 May 2025, 14:00 CET Exhibit 99.1
Slide 2: Management Report
Management Report 2 1 Operations Development 2024 & Q1 2025 and Outlook 2025 Prof. Dr. Ugur Sahin, Chief Executive Officer & Co-Founder Financial Development 2024 & Q1 2025 and Financial Outlook 2025 Jens Holstein, Chief Financial Officer
Slide 3: Operations Development 2024 & Q1 2025 and Outlook 2025
Operations Development 2024 & Q1 2025 and Outlook 2025 Prof. Dr. Ugur Sahin, CEO & Co-Founder1
Slide 4: This Slide Presentation Includes Forward-Looking Statements
4 This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profi
Slide 5: Building a Global Immunotherapy Powerhouse
Building a Global Immunotherapy Powerhouse Translating Science into Survival
Slide 6: Leveraging Our COVID-19 Vaccine Business Model and Balance Sheet for Sustainable Value Creation
Leveraging Our COVID-19 Vaccine Business Model and Balance Sheet for Sustainable Value Creation 6 1. Partnered with Pfizer. Multi-product portfolioPotential first launches in oncologyData updates across pipeline Cash generative COVID-19 vaccine business1 Balance sheet Financial Strength Progressive
Slide 7: Diversified Oncology Pipeline
Diversified Oncology Pipeline
Slide 8: Root Cause of Cancer Treatment Failure
Interindividual variability & intratumoral heterogeneity Root Cause of Cancer Treatment Failure Cancer cells Genetically Diverse & Adaptable Cancer evolution 5-20 Years – up to 10,000 mutationsIndividual patients 8 Alexandrov L et al., Nature 2019; Kandoth C et al., Nature 2013; Yizhak K et al., Sci
Slide 9: Uniquely Positioned to Combine Approaches to Transform Cancer Care
Space for curative approaches Immunomodulators mRNA cancer immunotherapies Targeted therapies Synergy1 Synergy1 Synergy1 • Focus on the critical IO pathways • Targeting different complementary pathways in cancer immunity cycle may promote a durable anti-tumor effect • Eliminate polyclonal residual d
Slide 10: 2025 Will Be an Important Year for Our Oncology Portfolio
10 1. Partnered with Genentech, a member of the Roche Group. 2025 Will Be an Important Year for Our Oncology Portfolio PD-L1/VEGF-A antibody BNT327 Novel mRNA cancer immunotherapy FixVac & iNeST1 Our next-generation IO-backbone Resected cancers (adjuvant, ctDNA+) Neoadjuvant, 1L advanced/metastatic
Slide 11: BNT327: Data from 1000 Patients Across Multiple Indications
BNT327: Data from 1000 Patients Across Multiple Indications Highlight the Potential to Establish a New Standard of Care 11 10+ indications studied1 >1000 patients enrolled 20+ clinical trials ongoing or planned 3 global potentially registrational trials Clinical activity across indications Including
Slide 12: Broad Combination Strategy Across Indications Aiming to Establish Next-Generation IO-Backbone
Broad Combination Strategy Across Indications Aiming to Establish Next-Generation IO-Backbone 12 1. NCI SEER https://training.seer.cancer.gov/index.html. 2.US incidence source: NIH and American Cancer Society data EU incidence source: European Cancer Information System Anti-PD-L1 Anti-VEGF Anti-PD-(
Slide 13: Biotheus Acquisition to Accelerate BNT327 Development Execution
Advancing BNT327 in multiple indications, aiming for first-to-market approvals Biotheus Acquisition to Accelerate BNT327 Development Execution 13 Anti-VEGF A Anti-PD-L1 VHH BNT327 development acceleration and expansion Clinical development capability establishment in China Full pipeline and platform
Slide 14: Scientific Capabilities Fueled by AI to Pioneer Personalized Immunotherapies
Our Leading Scientific Capabilities are Fueled by AI to Pioneer Personalized Immunotherapies 14 1. Partnered with Genentech, a member of the Roche Group. 2. From trials BNT122-01, GO39733, GO40558 and ML41081; 3. Castle et al., Journal of Cancer Research and Therapeutics, 2011; 4.“Top 500, The List”
Slide 15: COVID-19 Vaccine Business
— COVID-19 Vaccine Business A SIONT=Gaq
Slide 16: Developing and Approving the First mRNA Medicine
16 >4.9 billion doses of BNT162b2 shipped >180 countries and territories3 The fastest vaccine development in the history of medicine1 The strongest launch of any pharmaceutical product2 Developing and Approving the First mRNA Medicine 1. Ball P., Nature. 2021; 2. Measured by sales recorded for a sin
Slide 17: Long-Term Need for Seasonally Adapted Vaccines Anticipated
Variant-adapted vaccines Designed to be effective against multiple variants of concern5 Long-term health consequences Accumulating evidence demonstrates that COVID-19 vaccination reduces long- COVID4 Continuous evolution Ongoing antigenic evolution of SARS-CoV-21,2 Risk remains high For severe COVID
Slide 18: Execution in 2024 and Q1 2025
— Execution in 2024 and Q1 2025
Slide 19: Execution in 2024 and Q1 2025
19 1. Partnered with Genentech, a member of the Roche Group; 2. Phase 2 data were reported for BNT111 (PR, 30 July 2024), Phase 1/2 and Phase 2 data for BNT113 (ESMO), Phase 1 data for BNT116 (AACR); BNT327 data included: Phase 1/2 in TNBC (ESMO, SABCS) and Phase 2 in NSCLC (ASCO). 3. In collaborati
Slide 20: Outlook 2025
— Outlook a 2025 ys 7 SIONT=CH
Slide 21: Strategic Priority Areas in 2025
21 Partnered with: 1. DualityBio; 2. Pfizer. Strategic Priority Areas in 2025 mRNA cancer immunotherapy BNT327 Commercial readiness in oncology COVID-19 vaccine2 » Expect first randomized data in the adjuvant setting (CRC) » Execute 7 ongoing Phase 2 trials and first novel combination trials » Advan
Slide 22: Advancing Our Vision for Oncology
Advancing Our Vision for Oncology: A Once In a Generation Opportunity to Transform Medicine for Cancer Patients Execute on late-stage trials for BNT327 and our mRNA cancer immunotherapy portfolio Continuation of our novel combination strategy Prepare and execute launches of multiple oncology product
Slide 23: Financial Development 2024 & Q1 2025 and Financial Outlook 2025
2 Financial Development 2024 & Q1 2025 and Financial Outlook 2025 Jens Holstein, CFO
Slide 24: 2024 Financial Execution Highlights
2024 Financial Execution Highlights1 24 Loss before tax € 2.77 € 678 m € 2.8 bn € 17.4 bn Total revenues Basic and diluted loss per share Total cash plus security investments2 1. Numbers are rounded to millions and billions of Euros in accordance with standard commercial practice. 2. Consists of cas
Slide 25: Full Year 2024 Results Compared to Full Year 2024 Financial Guidance
Full Year 2024 Results Compared to Full Year 2024 Financial Guidance 25 FY 2024 Updated Guidance (published as part of the Q3 2024 earnings presentation) FY 2024 Results1 FY 2024 revenues Total revenues €2,500 – €3,100 m (lower end) €2,751 m FY 2024 expenses and capex Research and development expens
Slide 26: Capital Transactions During FY 2024 and First Quarter 2025
Capital Transactions During FY 2024 and First Quarter 2025 26 FY 2024: Employee Programs Use of ADSs1 held in treasury Period Number of issued ADSs Percentage of share capital2 Issue price Volume3 ESOP 2018 Settlement May to Nov. 2024 63,857 0.03% €83.55 €5.3 million LTI 2020 Board Settlement Aug. 2
Slide 27: Q1 2025 Financial Execution Highlights
Q1 2025 Financial Execution Highlights1 27 Loss before tax € 1.73 € 445 m € 183 m € 15.9 bn Total revenues Basic and diluted loss per share Total cash plus security investments2 1. Numbers have been rounded. 2. Cash and cash equivalents plus security investments as of March 31, 2025, reached €15,854
Slide 28: 2025 Financial Year Guidance
2025 Financial Year Guidance1 28 FY 2025 Guidance Planned FY 2025 revenues Total revenues €1,700 – €2,200 m Planned FY 2025 expenses and capex Research and development expenses €2,600 – €2,800 m Sales, general and administrative expenses €650 – €750 m Capital expenditure for operating activities €25
Slide 29: Save the date: Annual Innovation Series November 11, 2025
Save the date Annual Innovation Series November 11, 2025
Slide 30: Thank you for your attention.
Thank you for your attention.
Slide 31: Abbreviation Directory
Abbreviation Directory n L nth line LTI Long-term incentive AACR American Association for Cancer Research M&A Merger and acquisitions ADC Antibody-drug conjugate MPM Malignant pleural mesothelioma AI Artificial intelligence mRNA Messenger ribonucleic acid ASCO American Society of Clinical Oncology M